Pharmacology of Drugs for Asthma

Introduction / Overview

Asthma is a chronic inflammatory disorder of the airways characterized by episodic bronchoconstriction, mucus hypersecretion, and airway remodeling. The prevalence of asthma has increased globally, with significant morbidity and mortality associated with exacerbations. Pharmacologic therapy remains the cornerstone of disease management, aiming to relieve acute symptoms, reduce airway hyperresponsiveness, and prevent long‑term complications. This monograph is designed to provide medical and pharmacy students with a comprehensive understanding of the pharmacology, clinical application, and safety considerations of asthma therapeutics. It addresses the following learning objectives:

• Identify the major drug classes approved for asthma management and their chemical classifications.
• Describe the pharmacodynamic mechanisms underlying bronchodilation and anti‑inflammatory effects.
• Explain the pharmacokinetic profiles of inhaled and systemic agents and their impact on dosing strategies.
• Recognize therapeutic indications, off‑label uses, and safety profiles of each drug class.
• Evaluate drug interactions, contraindications, and special population considerations pertinent to asthma therapy.

Classification

Bronchodilators

Bronchodilators are subdivided into short‑acting and long‑acting agents, each targeting specific receptors to induce smooth‑muscle relaxation.

• Short‑acting β₂‑adrenergic agonists (SABAs) – e.g., albuterol, levalbuterol.
• Long‑acting β₂‑adrenergic agonists (LABAs) – e.g., salmeterol, formoterol, vilanterol.
• Anticholinergics – short‑acting (ipratropium bromide) and long‑acting (tiotropium bromide).
• Leukotriene receptor antagonists (LTRAs) – montelukast, zafirlukast, pranlukast.

Anti‑Inflammatory Agents

• Inhaled corticosteroids (ICS) – fluticasone propionate, budesonide, beclomethasone dipropionate, mometasone furoate, ciclesonide, triamcinolone acetonide.
• Systemic corticosteroids – prednisone, prednisolone, methylprednisolone.
• Leukotriene modifiers – as above.
• Biologic agents – omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, lebrikizumab, tezepelumab.

Adjunctive and Emerging Therapies

• Immunomodulators – montelukast (as LTRA), but also new agents targeting epithelial cytokines.
• Other bronchodilators – phosphodiesterase‑4 inhibitors (e.g., roflumilast) in COPD overlap.
• Combination inhalers – fixed‑dose LABA/ICS, LABA/ICS/LABA.

Mechanism of Action

β₂‑Adrenergic Agonists

Binding to β₂ receptors on airway smooth‑muscle triggers G_s protein activation, stimulating adenylyl cyclase and elevating intracellular cAMP. The increased cAMP activates protein kinase A, which phosphorylates myosin light‑chain kinase, resulting in reduced myosin light‑chain phosphorylation and subsequent smooth‑muscle relaxation. LABAs exhibit a slower onset but prolonged action due to a higher affinity for β₂ receptors and reduced desensitization.

Anticholinergics

Antagonism of muscarinic M₃ receptors inhibits G_q signaling, decreasing phospholipase C activity, inositol 1,4,5‑trisphosphate production, and calcium release. The resulting lower intracellular calcium reduces smooth‑muscle contraction. Long‑acting anticholinergics possess higher receptor affinity and longer half‑life.

Inhaled Corticosteroids

ICS act via glucocorticoid receptors that translocate to the nucleus and modulate gene transcription. They inhibit pro‑inflammatory transcription factors such as NF‑κB and AP‑1, downregulating cytokines (IL‑4, IL‑5, IL‑13), chemokines, and adhesion molecules. Additionally, they promote the synthesis of anti‑inflammatory proteins such as annexin‑A1. The net effect is a reduction in eosinophilic inflammation, mucus production, and airway hyperresponsiveness.

Leukotriene Modifiers

Montelukast and related agents competitively inhibit CysLT₁ receptors on bronchial smooth‑muscle and inflammatory cells. This blockade prevents leukotriene D₄‑induced bronchoconstriction, vascular permeability, and eosinophil recruitment. LTRAs also inhibit the synthesis of prostaglandin D₂, contributing to reduced inflammation.

Biologic Agents

Omalizumab binds circulating IgE, preventing IgE‑mediated activation of mast cells and basophils. Mepolizumab, reslizumab, and benralizumab target IL‑5 or its receptor, reducing eosinophil survival and recruitment. Dupilumab blocks IL‑4 receptor α, inhibiting IL‑4 and IL‑13 signaling pathways. These cytokines are pivotal in type 2 inflammation, and blockade leads to decreased airway inflammation and improved lung function.

Pharmacokinetics

Absorption

Inhaled agents achieve rapid local deposition in the airways; systemic absorption is limited for most inhaled corticosteroids due to high first‑pass metabolism and low oral bioavailability. Oral leukotriene antagonists exhibit moderate bioavailability (≈ 60–80 %) and extensive hepatic metabolism. Systemic corticosteroids display variable absorption; oral prednisone achieves ~80 % bioavailability, while intravenous methylprednisolone bypasses first‑pass effects.

Distribution

ICS are lipophilic and bind extensively to plasma proteins, primarily albumin; they display a large volume of distribution (≈ 20–30 L). LABAs exhibit moderate protein binding (~40 %) and widespread distribution. Systemic corticosteroids distribute into most tissues, with high penetration into pulmonary tissue but also into adipose tissue due to lipophilicity.

Metabolism

ICS are predominantly metabolized by cytochrome P450 3A4 (CYP3A4) in the liver. The metabolites are inactive and excreted renally. LABAs are metabolized via CYP2D6 and CYP3A4 to inactive metabolites. Oral LTRAs undergo hepatic metabolism via CYP3A4 and CYP1A2. Systemic corticosteroids are metabolized by CYP3A4, CYP2C9, and other pathways, producing active metabolites that maintain anti‑inflammatory activity.

Excretion

Active metabolites of inhaled agents are excreted via the kidneys. The half‑life of fluticasone propionate is ~7 h, whereas budesonide’s half‑life is ~2–3 h. LABAs have half‑lives ranging from 4–6 h, allowing once‑daily dosing. Systemic corticosteroids have variable elimination half‑lives; prednisone’s half‑life is ~3–4 h, while methylprednisolone’s is ~7–8 h. Renal excretion accounts for the majority of elimination, with a small proportion excreted unchanged in urine.

Dosing Considerations

For inhaled agents, the dose is typically expressed in micrograms per inhalation. Peak concentrations are achieved within minutes of inhalation. Inhaler technique profoundly influences deposition; therefore, patient education is critical. Oral LTRAs are dosed once or twice daily, with minimal titration needed. Systemic corticosteroids require careful tapering to avoid adrenal suppression; the dose should be reduced to the lowest effective level as soon as clinically feasible.

Therapeutic Uses / Clinical Applications

Bronchodilators

SABAs are first‑line rescue medications for acute bronchoconstriction. LABAs are used as controller therapy in combination with inhaled corticosteroids for persistent asthma. Anticholinergics, particularly tiotropium, are indicated in combination with LABAs in patients with uncontrolled symptoms despite high‑dose inhaled corticosteroids. LTRAs are employed mainly for exercise‑induced bronchospasm and as adjuncts in patients with concomitant allergic rhinitis.

Anti‑Inflammatory Agents

ICS are the foundational controller therapy for persistent asthma across all age groups, with dose adjustments based on disease severity. Systemic corticosteroids are reserved for acute exacerbations, severe persistent asthma, or when inhaled therapy fails. Biologic agents target specific pathways in severe, uncontrolled asthma with elevated IgE or eosinophil counts, and are indicated in patients refractory to high‑dose inhaled corticosteroids and LABAs.

Adjunctive Therapies

Combination inhalers facilitate adherence by reducing the number of devices. Leukotriene modifiers are often added to inhaled therapy in patients with aspirin‑exacerbated respiratory disease (AERD) or as monotherapy in mild intermittent asthma. Theophylline and phosphodiesterase‑4 inhibitors are seldom used in asthma but may be considered in patients with overlapping COPD or severe chronic inflammation.

Off‑Label Uses

Levetiracetam, a β₂‑agonist, has occasionally been used off‑label for severe asthma in pediatric populations. Omalizumab has been employed in chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyposis. Biologics are sometimes off‑label utilized in severe asthma patients with comorbid atopic dermatitis or eosinophilic disorders.

Adverse Effects

Bronchodilators

SABAs may cause tremor, tachycardia, palpitations, hypokalemia, and paradoxical bronchoconstriction. LABAs can lead to tachyphylaxis, arrhythmias, and, in rare cases, increased mortality when used as monotherapy. Anticholinergics may induce dry mouth, blurred vision, urinary retention, and cognitive impairment in elderly patients. LTRAs are generally well tolerated but can cause headache, abdominal discomfort, and, rarely, neuropsychiatric events.

Inhaled Corticosteroids

Local side effects include oral thrush, dysphonia, and cough. Systemic absorption may lead to adrenal suppression, growth retardation in children, osteoporosis, cataracts, and skin thinning. The risk of systemic effects is dose‑dependent, and high‑dose inhalers should be monitored closely.

Systemic Corticosteroids

Common adverse reactions encompass weight gain, hypertension, hyperglycemia, mood changes, osteoporosis, and increased infection susceptibility. Long‑term use risks include Cushingoid features, adrenal insufficiency, and cataract formation.

Biologic Agents

Omalizumab can cause anaphylaxis, especially during the first infusion; therefore, patients should be monitored for 30 minutes post‑administration. Mepolizumab, reslizumab, and benralizumab may result in mild injection‑site reactions. Dupilumab has been associated with conjunctivitis, injection‑site reactions, and, rarely, eosinophilic pneumonia. All biologics carry a risk of hypersensitivity reactions.

Black Box Warnings

LABAs have a black box warning against monotherapy due to increased asthma‑related deaths. Systemic corticosteroids carry warnings for adrenal suppression and bone loss with chronic use. Omalizumab is accompanied by anaphylaxis risk.

Drug Interactions

β₂‑Adrenergic Agonists

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can reduce the metabolism of LABAs, potentially increasing bradycardia risk. β‑Blockers may antagonize β₂ agonist effects, leading to inadequate bronchodilation.

Inhaled Corticosteroids

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) may elevate systemic exposure, increasing the risk of adrenal suppression. Conversely, CYP3A4 inducers (rifampin, carbamazepine) can reduce efficacy.

Leukotriene Modifiers

Co‑administration with strong CYP3A4 inhibitors can raise montelukast levels, potentially increasing neuropsychiatric adverse events.

Biologic Agents

Omalizumab requires careful monitoring when combined with other biologics (e.g., anti‑IL‑5) due to overlapping immunomodulatory effects. Dupilumab may potentiate effects of other agents that modulate IL‑4/IL‑13 pathways.

General Contraindications

Patients with uncontrolled cardiac arrhythmias should avoid LABAs. Severe hepatic impairment may increase systemic exposure to inhaled corticosteroids. Anticholinergics are contraindicated in patients with narrow‑angle glaucoma or prostatic hyperplasia.

Special Considerations

Pregnancy / Lactation

ICS are classified as pregnancy category C; however, uncontrolled asthma poses higher risks to the fetus than low‑dose inhaled therapy. LABAs and anticholinergics are also category C. Systemic corticosteroids fall into category D; risks include fetal growth restriction and adrenal suppression. Biologics are not recommended during pregnancy and lactation due to limited data.

Pediatric Considerations

ICS are preferred for persistent asthma in children; dosing is weight‑based and escalation is guided by symptom control. LABAs should not be prescribed alone. Growth suppression is a concern with high‑dose or prolonged use; monitoring height and weight is advised. Leukotriene modifiers are well tolerated in pediatric populations and are often used for aspirin‑exacerbated respiratory disease.

Geriatric Considerations

Elderly patients are more susceptible to anticholinergic side effects, such as cognitive impairment and urinary retention. LABAs may pose arrhythmic risks in patients with underlying cardiac disease. Dose adjustments are not routinely required for inhaled agents, but monitoring for systemic side effects is essential.

Renal / Hepatic Impairment

ICS exhibit minimal renal excretion; thus, dose adjustment is not required in renal impairment. In hepatic impairment, metabolism of inhaled steroids may be reduced, potentially increasing systemic exposure; careful monitoring is recommended. Oral leukotriene antagonists may accumulate in severe hepatic dysfunction; dose reduction or avoidance is suggested. Systemic corticosteroids require dose adjustment in hepatic failure due to altered metabolism.

Summary / Key Points

• Bronchodilators provide rapid symptom relief; LABAs must be combined with inhaled corticosteroids to mitigate mortality risk.
• Inhaled corticosteroids remain the cornerstone of controller therapy and are dose‑responsive with minimal systemic exposure when properly delivered.
• Leukotriene modifiers serve as adjuncts in specific phenotypes such as aspirin‑exacerbated respiratory disease and exercise‑induced bronchospasm.
• Biologic agents target distinct immunologic pathways and are reserved for severe, uncontrolled asthma with specific biomarkers.
• Drug interactions, especially involving CYP3A4, must be considered to avoid reduced efficacy or increased toxicity.
• Special populations—including pregnant patients, children, and the elderly—require tailored dosing strategies and vigilant monitoring for adverse effects.
• Patient education on inhaler technique and adherence is pivotal for optimizing therapeutic outcomes.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.